Ryan Replogle

Sumitomo Pharma America, Inc.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma's U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company. Community Guidelines: https://www.us.sumitomo-pharma.com/social-media/index.html